七氟醚对比异丙酚复合瑞芬太尼对幕上胶质瘤患者术后神经认知功能的影响

注册号:

Registration number:

ChiCTR-IOR-16009177 

最近更新日期:

Date of Last Refreshed on:

2018-05-27 21:38:26 

注册时间:

Date of Registration:

2016-09-08 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

七氟醚对比异丙酚复合瑞芬太尼对幕上胶质瘤患者术后神经认知功能的影响

Public title:

Sevoflurane Versus PRopofol Combined with Remifentanil Anesthesia Impact on Postoperative Neurological Function in Supratentorial Gliomas (SPRING)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

吸入麻醉对比全静脉麻醉对幕上胶质瘤患者术后神经认知功能的影响

Scientific title:

Inhalational versus intravenous anesthesia impact on neurological function and neurocognition in patients with supratentorial gliomas

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

林楠 

研究负责人:

林楠 

Applicant:

Nan LIN 

Study leader:

Nan LIN 

申请注册联系人电话:

Applicant telephone:

+86 10-13810108927

研究负责人电话:

Study leader's
telephone:

+86 10-13810108927

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

linnan127@163.com

研究负责人电子邮件:

Study leader's E-mail:

linnan127@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市东城区天坛西里6号,北京,中国

研究负责人通讯地址:

北京市东城区天坛西里6号北京天坛医院

Applicant address:

6 Tiantan Street West, Dongcheng District, Beijing, China

Study leader's address:

6 Tiantan Street West, Dongcheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

100050

研究负责人邮政编码:

Study leader's postcode:

100050

申请人所在单位:

首都医科大学附属北京天坛医院

Applicant's institution:

Beijing Tiantan Hospital, Capital Medical University

研究负责人所在单位:

首都医科大学附属北京天坛医院

Affiliation of the Leader:

Beijing Tiantan Hospital, Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

ChiECRCT-20160051

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国注册临床试验伦理审查委员会

Name of the ethic committee:

China Ethics Committee of Registering Clinical Trials

伦理委员会批准日期:

Date of approved by ethic committee:

2016-09-22 00:00:00

伦理委员会联系人:

吴泰相

Contact Name of the ethic committee:

Tai Xiang Wu

伦理委员会联系地址:

四川大学华西医院,中国四川省成都市国学巷37号行政楼八角亭2092室

Contact Address of the ethic committee:

West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 18980604562

伦理委员会联系人邮箱:

Contact email of the ethic committee:

Chictr@scu.edu.cn

研究实施负责(组长)单位:

首都医科大学附属北京天坛医院

Primary sponsor:

Beijing Tiantan Hospital, Capital Medical University

研究实施负责(组长)单位地址:

北京市东城区天坛西里6号,北京,中国

Primary sponsor's address:

6 Tiantan Street West, Dongcheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京天坛医院

具体地址:

北京市东城区天坛西里6号,北京,中国

Institution
hospital:

Beijing Tiantan Hospital, Capital Medical University

Address:

6 Tiantan Street West, Dongcheng District, Beijing, China

经费或物资来源:

北京市医管局青苗项目

Source(s) of funding:

Beijing Municipal Administration of Hospital's Youth Programme

研究疾病:

颅内幕上胶质瘤  

Target disease:

Supratentorial Glioma

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

(1)主要目的:观察吸入麻醉和全凭静脉麻醉对择期行神经外科开颅手术的幕上胶质瘤患者早期神经认知功能的影响。 (2)次要目的:观察吸入麻醉和全凭静脉麻醉对幕上胶质瘤的择期开颅患者全身血流动力学、颅内生理变化、麻醉恢复质量、疼痛评分、麻醉花费和全身应激反应的血、尿生化指标的影响。  

Objectives of Study:

1. Primary purpose: To investigate neurological function and neurocognition in early postoperative period for patient with supratentorial gliomas under inhalational general anesthesia compared to intravenous general anesthesia; 2. Secondary purpose: To compare the effects of inhalational general anesthesia versus intravenous general anesthesia on hemodynamics, cerebral physiology, anesthesia recovery quality, pain score, anesthesia expenses and stress response in patients with supratentorial gliomas under elective craniotomy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 患者无法理解和配合神经认知功能评估
2. 急诊开颅手术或由于特殊原因择期改为急诊的开颅手术
3. 合并创伤性颅内损伤、颅内出血、脑血管病和岛叶损伤的患者
4. 由于明确的手术因素、肿瘤部位、颅内损伤所造成的苏醒延迟、机械通气和镇静药物依赖的患者
5. 难以控制的高血压和严重的心血管疾病影响心功能的患者(心功能≥III级)
6. 有明确的麻醉药物过敏史
7. 下丘脑功能受损的患者
8. 严重的内分泌疾病影响代谢指标的患者
9. 合并精神异常的患者
10. 药物和酒精滥用的患者
11. 孕期及哺乳期女性
12. 接受放疗或化疗的患者
13. 合并神经肌肉疾病的患者
14. 合并感染性和/或免疫性疾病并生物标记物呈阳性的患者

Exclusion criteria:

1. Unable to comprehend and cooperate with the neurologic examination;
2. Emergency craniotomy or changed into emergency from elective craniotomy;
3. With traumatic brain injury, hemorrhage or cerebral vascular diseases;
4. Prolonged emergence, mechanical ventilation and sedation dependence due to definite reason eg. surgery itself, tumor location etc.;
5. Uncontrolled hypertension and severe heart diseases that impair cardiac function (New York Heart Association Functional Classification≥III);
6. History of related anesthetic allergy;
7. With hypothalamus dysfunction;
8. Severe endocrine system dysfunction that impair metabolic index;
9. Impaired mental status;
10. Drug and/or alcohol abuse;
11. Pregnant and/or lactation period woman;
12. Accept radiotherapy and/or chemotherapy before surgery;
13. With neuromuscular diseases;
14. With infectious and/or immune diseases that have positive biomarker(s).

研究实施时间:

Study execute time:

From 2017-01-01 00:00:00 To 2020-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2018-05-28 00:00:00 To 2020-12-31 00:00:00

干预措施:

Interventions:

组别:

静脉全麻组

样本量:

176

Group:

TIVA

Sample size:

干预措施:

异丙酚复合瑞芬太尼

干预措施代码:

Intervention:

Propofol combined with Remifentanil

Intervention code:

组别:

吸入麻醉组

样本量:

176

Group:

Inhalational

Sample size:

干预措施:

七氟醚复合瑞芬太尼

干预措施代码:

Intervention:

Sevoflurane combined with Remifentanil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京天坛医院 

单位级别:

局级,3级甲等 

Institution
hospital:

Beijing Tiantan Hospital, Capital Medical University

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

NIH卒中评分

指标类型:

主要指标

Outcome:

NIH Stroke Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

改良的NIH卒中评分

指标类型:

主要指标

Outcome:

Modified NIH Stroke Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

简易精神量表

指标类型:

主要指标

Outcome:

Mini–Mental State Examination

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

头部核磁结果

指标类型:

次要指标

Outcome:

Head MRI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

病理诊断

指标类型:

次要指标

Outcome:

Pathological diagnosis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血压

指标类型:

次要指标

Outcome:

Blood pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率

指标类型:

次要指标

Outcome:

heart rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血氧饱和度

指标类型:

次要指标

Outcome:

SpO2

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

麻醉深度

指标类型:

次要指标

Outcome:

Depth of Anesthesia

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑松弛度

指标类型:

次要指标

Outcome:

brain relaxation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

麻醉恢复期质量

指标类型:

次要指标

Outcome:

Anesthesia Recovery Quality

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后疼痛的视觉模拟评分

指标类型:

次要指标

Outcome:

Visual Analog Scale for postoperative pain

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后并发症

指标类型:

次要指标

Outcome:

postoperative complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

麻醉花费

指标类型:

次要指标

Outcome:

Anesthesia expenses

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

应激和免疫反应生物标记物

指标类型:

次要指标

Outcome:

Stress and immune reaction biomarker

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

麻醉恢复质量满意度量表

指标类型:

次要指标

Outcome:

QoR-40 Quality of Recovery from Anesthesia

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

符合纳入标准的患者按照计算机生成的随机数字表随机分为两组,即七氟醚+瑞芬太尼 或 异丙酚+瑞芬太尼。随机区组长度为4,分配比率为1:1。

Randomization Procedure (please state who generates the random number sequence and by what method):

Patients who met the protocol criteria were randomly assigned to one of two intervention study groups, labeled ‘Prop+Remi group’, ‘Sevo+Remi group’. Randomization was based on a computer generated random digits table. Permuted-block randomization was used with a block size of 4 and an allocation ratio of 1:1.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

由于药物给予方式的特点(吸入或静脉),因此无法做到盲法。

Blinding:

Blinding can not be achieved because of the distinct administration method: inhalational or intravenous.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后6个月内将通过中国临床试验注册平台公开数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

the data will be in publicity through Chinese clinical trial registration system within six months after the trial ccomplete

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采用excel表格和SPSS数据库数据保管

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

the data will be saved and managed through Excel in microsoft office and SPSS database.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2016-09-08 23:04:22